logo-loader

Silence Therapeutics names experienced biotech boss as its new chief executive officer with immediate effect

Published: 22:14 17 Jul 2018 AEST

New boss handshake
He has also been managing partner of Sund Capital, ApS, a Nordic healthcare investment fund

Silence Therapeutics PLC (LON:SLN) has announced the appointment of Dr David Horn Solomon, an experienced public company biotech boss and biotech investor as its new chief executive officer with immediate effect.

The AIM-listed group, a leader in the discovery and development of novel RNA therapeutics, noted that Solomon was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015.

READ: Silence Therapeutics pleased with pipeline progress of Quark Pharma

Under his leadership, the company went public on NASDAQ OMX and its lead product, Adlixin, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by French drugs firm Sanofi as a monotherapy and in combination with Lantus as Soliqua.

Solomon has also been the CEO of Bionor Pharma ASA (OSL:BIONOR) and Akari Therapeutics PLC (NASDAQ:AKTX), and managing partner of Sund Capital, ApS, a Nordic healthcare investment fund.

Commenting on the appointment, Annalisa Jenkins, Silence Therapeutics’ executive chair, said: “Having held senior management roles in both the US and Europe, David brings extensive international leadership experience in the biotech industry with a track record of successful pipeline delivery, financing and deal-making.

She added: “With David at the helm as CEO, supported by a very experienced team and Board, Silence is in a strong position to maximise the potential of our IP and technology through strong collaborations and the advancement of our internal programmes toward the clinic, with our lead candidate SLN124 becoming a clinical stage asset in the coming year."

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

1 hour, 16 minutes ago